September 01, 2005 10:02 ET

New Study Finds Early Life Second-Hand Smoke Exposure Can Produce Life-Long Respiratory Problems; Nymox (NASDAQ: NYMX) TobacAlert™ Product Detects Second-Hand Smoke Exposure

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Sep 1, 2005) -

A newly published study of 35,000 adult non-smokers in Singapore has found that those who lived with a smoker during childhood had more than twice as many respiratory problems as those who did not have exposure. The new study, published by researchers at the National Institute of Environmental Health Sciences, the University of Minnesota, and the National University of Singapore, was published online in Thorax. It is the largest study to date on the effects of childhood exposure to environmental tobacco smoke (ETS) on later respiratory disease. The data for this study involved 35,000 non-smokers who provided information regarding ETS before and after age 18. A second recent study of 60,182 never-smokers followed over a seven year period found a marked increase in the risk of lung cancer for adults who reported regular exposure to second-hand smoke during childhood (BMJ 2005; 330(7486):277)

Nymox Pharmaceutical (NASDAQ:NYMX) makes TobacAlert™, an easy-to-use, cost-effective product that allows for on-site testing for second-hand smoke exposure. TobacAlert™ can be used at home, at school or in the workplace. No instruments are required and results are provided within minutes.

"The serious health risks posed by second-hand smoke exposure to children and adolescents cannot be ignored," said Brian Doyle, Nymox's Manager of Global Sales and Marketing. "People are often unaware of the nature and extent of second-hand smoke exposure, both to themselves and to their family. TobacAlert™ offers a convenient and easy way to get some objective answers."

TobacAlert™ is available at over 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX